Tricyclic antidepressants delay the need for dopaminergic therapy in early Parkinson's disease

Movement Disorders

Volumn 27, Issue 7, 2012, Pages 880-887

  Paumier, Katrina L ^a   Siderowf, Andrew D ^b   Auinger, Peggy ^c   Oakes, David ^c   Madhavan, Lalitha ^a   Espay, Alberto J ^a,d   Revilla, Fredy J ^a,d   Collier, Timothy J ^e  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c UNIVERSITY OF ROCHESTER SCHOOL OF MEDICINE AND DENTISTRY   (United States)

^d UNIVERSITY OF CINCINNATI   (United States)

^e MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

Antidepressants; Depression; Disease modifying; Parkinson's disease; Retrospective study

Indexed keywords

AMFEBUTAMONE; AMITRIPTYLINE; FLUVOXAMINE; MIRTAZAPINE; PAROXETINE; PLACEBO; SERTRALINE; TRAZODONE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ANALYSIS OF COVARIANCE; ARTICLE; CELL SURVIVAL; CONTROLLED STUDY; DEPRESSION; DISABILITY; DISEASE COURSE; DISEASE SEVERITY; DOPAMINERGIC ACTIVITY; FEMALE; HUMAN; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; META ANALYSIS; MOTOR DYSFUNCTION; PARKINSON DISEASE; PRIORITY JOURNAL; PROPORTIONAL HAZARDS MODEL; TREATMENT OUTCOME; UNIFIED PARKINSON DISEASE RATING SCALE;

EID: 85027927635     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.24978     Document Type: Article

References (37)

1. Dooneief G, Mirabello E, Bell K, Marder K, Stern Y, Mayeux R. An estimate of the incidence of depression in idiopathic Parkinson's disease. Arch Neurol 1992; 49: 305-307.
2. McDonald WM, Richard IH, DeLong MR. Prevalence, etiology, and treatment of depression in Parkinson's disease. Biol Psychiatry 2003; 54: 363-375.
3. Papapetropoulos S, Ellul J, Argyriou AA, Chroni E, Lekka NP. The effect of depression on motor function and disease severity of Parkinson's disease. Clin Neurol Neurosurg 2006; 108: 465-469.
4. Peng Q, Masuda N, Jiang M, et al. The antidepressant sertraline improves the phenotype, promotes neurogenesis and increases BDNF levels in the R6/2 Huntington's disease mouse model. Exp Neurol 2008; 210: 154-163.
5. Sairanen M, O'Leary OF, Knuuttila JE, Castren E. Chronic antidepressant treatment selectively increases expression of plasticity-related proteins in the hippocampus and medial prefrontal cortex of the rat. Neuroscience 2007; 144: 368-374.
6. Zschocke J, Zimmermann N, Berning B, Ganal V, Holsboer F, Rein T. Antidepressant drugs diversely affect autophagy pathways in astrocytes and neurons-dissociation from cholesterol homeostasis. Neuropsychopharmacology 2011; 36: 1754-1768.
7. Zhao Z, Zhang HT, Bootzin E, Millan MJ, O'Donnell JM. Association of changes in norepinephrine and serotonin transporter expression with the long-term behavioral effects of antidepressant drugs. Neuropsychopharmacology 2009; 34: 1467-1481.
8. Jang SW, Liu X, Chan CB, et al. Amitriptyline is a TrkA and TrkB receptor agonist that promotes TrkA/TrkB heterodimerization and has potent neurotrophic activity. Chem Biol 2009; 16: 644-656.
9. Fahn S. Parkinson disease, the effect of levodopa, and the ELLDOPA trial. Earlier vs later L-DOPA. Arch Neurol 1999; 56: 529-535.
10. Shults CW, Oakes D, Kieburtz K, et al. Effects of coenzyme Q10 in early Parkinson disease: evidence of slowing of the functional decline. Arch Neurol 2002; 59: 1541-1550.
11. A controlled trial of rasagiline in early Parkinson disease: the TEMPO Study. Arch Neurol 2002; 59: 1937-1943.
12. Wang LH, Johnson EM, Jr. Mixed lineage kinase inhibitor CEP-1347 fails to delay disability in early Parkinson disease. Neurology 2008; 71: 462; author reply 462-463.
13. A randomized, double-blind, futility clinical trial of creatine and minocycline in early Parkinson disease. Neurology 2006; 66: 664-671.
14. NINDS NET-PD Investigators. A randomized clinical trial of coenzyme Q10 and GPI-1485 in early Parkinson disease. Neurology 2007; 68: 20-28.
15. Marras C, Lang AE. Outcome measures for clinical trials in Parkinson's disease: achievements and shortcomings. Exp Rev Neurother 2004; 4: 985-993.
16. Yesavage JA, Brink TL, Rose TL, et al. Development and validation of a geriatric depression screening scale: a preliminary report. J Psychiatr Res 1982; 17: 37-49.
17. Hamilton M. Rating depressive patients. J Clin Psychiatry 1980; 41: 21-24.
18. Beck AT, Ward CH, Mendelson M, Mock J, Erbaugh J. An inventory for measuring depression. Arch Gen Psychiatry 1961; 4: 561-571.
19. Frisina PG, Tenenbaum HR, Borod JC, Foldi NS. The effects of antidepressants in Parkinson's disease: a meta-analysis. Int J Neurosci 2008; 118: 667-682.
20. Menza M, Dobkin RD, Marin H, et al. A controlled trial of antidepressants in patients with Parkinson disease and depression. Neurology 2009; 72: 886-892.
21. Bxarone P, Poewe W, Albrecht S, et al. Pramipexole for the treatment of depressive symptoms in patients with Parkinson's disease: a randomised, double-blind, placebo-controlled trial. Lancet Neurol 2010; 9: 573-580.
22. Ricci V, Pomponi M, Martinotti G, et al. Antidepressant treatment restores brain-derived neurotrophic factor serum levels and ameliorates motor function in Parkinson disease patients. J Clin Psychopharmacol 2010; 30: 751-753.
23. Chung YC, Kim SR, Jin BK. Paroxetine prevents loss of nigrostriatal dopaminergic neurons by inhibiting brain inflammation and oxidative stress in an experimental model of Parkinson's disease. J Immunol 2010; 185: 1230-1237.
24. Jin Y, Lim CM, Kim SW, et al. Fluoxetine attenuates kainic acid-induced neuronal cell death in the mouse hippocampus. Brain Res 2009; 1281: 108-116.
25. Chadwick W, Mitchell N, Caroll J, et al. Amitriptyline-mediated cognitive enhancement in aged 3xtg Alzheimer's disease mice is associated with neurogenesis and neurotrophic activity. PLoS One 2011; 6: e21660.
26. Chung YC, Kim SR, Park JY, et al. Fluoxetine prevents MPTP-induced loss of dopaminergic neurons by inhibiting microglial activation. Neuropharmacology 2010; 60: 963-974.
27. Paumier KL, Sortwell C, Daley BF, et al. Tricyclic antidepressant treatment protects dopamine neurons and increases neurotrophic factors within the nigrostriatal system. Program No. 45.13/E34. 2009 Neuroscience Meeting Planner. Chicago, IL: Society for Neuroscience, 2009. Online.
28. Menza M, Dobkin RD, Marin H, et al. The impact of treatment of depression on quality of life, disability and relapse in patients with Parkinson's disease. Mov Disord 2009; 24: 1325-1332.
29. Ravina B, Camicioli R, Como PG, et al. The impact of depressive symptoms in early Parkinson disease. Neurology 2007; 69: 342-347.
30. Chen P, Kales HC, Weintraub D, Blow FC, Jiang L, Mellow AM. Antidepressant treatment of veterans with Parkinson's disease and depression: analysis of a national sample. J Geriatr Psychiatry Neurol 2007; 20: 161-165.
31. Poewe WH, Wenning GK. The natural history of Parkinson's disease. Ann Neurol 1998; 44( 3 Suppl 1): S1-S9.
32. Rascol O, Fitzer-Attas CJ, Hauser R, et al. A double-blind, delayed-start trial of rasagiline in Parkinson's disease (the ADAGIO study): prespecified and post-hoc analyses of the need for additional therapies, changes in UPDRS scores, and non-motor outcomes. Lancet Neurol 2011; 10: 415-423.
33. The Unified Parkinson's Disease Rating Scale (UPDRS): status and recommendations. Mov Disord 2003; 18: 738-750.
34. Harrison MB, Wylie SA, Frysinger RC, et al. UPDRS activity of daily living score as a marker of Parkinson's disease progression. Mov Disord 2009; 24: 224-230.
35. Schrag A, Spottke A, Quinn NP, Dodel R. Comparative responsiveness of Parkinson's disease scales to change over time. Mov Disord 2009; 24: 813-818.
36. Poewe WH, Wenning GK. The natural history of Parkinson's disease. Neurology 1996; 47( 6 Suppl 3): S146-S152.
37. Schrag A. Quality of life and depression in Parkinson's disease. J Neurol Sci 2006; 248: 151-157.